#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE.

In re application of: PedroMATA LOPEZ, et al.

Serial No.: 10/542,937

Filed

Group No.

1634

July 21, 2005 Examiner:

Stephen Thomas Kaunshoe

Confirmation No : 5381 Ferr METHOD AND DEVICE FOR THE DETECTION OF MUTATIONS IN ISOLATED GENE SEQUENCES OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR (LDL-R) WHICH IS

ASSOCIATED WITH FAMILIAL HYPERCHOLESTROLEMIA

### SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY. AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE

# AND/OR AMINO ACID SEQUENCE

	CERTIFICATION DIMEN 3/ C.P.R. LO(B) and I.10
	(When using Express Mail, the Express Mail label number immidatory:
	Express Mail certification is optional.)
hereby certify that, on	the date shown below, this correspondence is being:
	MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450. Alexandria, VA 22313-1450

## 37 C.F.R. 1.8(a)

with sufficient postage as first class mail.

#### 37 C.F.R. L10\*

as "Express Mail Post Office to Address" Mailing Label No \_\_\_\_\_\_ (mandatory)

#### TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office to (571)-273-8300

Date: March 31, 2011

EFS.WEB transmitted electronically

Janet I. Cord

(type or print name of person certifying

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing, 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is on oversight that can be avoided by the exercise of reasonable care, requests for wower of this requirement will not be granted on pelition." Notice of Oct. 24, 1996, 60 Fed. Rog. 56,439, at 56,442.

- 1. I/!This replies to the Office Letter dated 04 March 2011
- NOTE: If these papers are filed infore the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and till of womening, the filing date based on the "Express bind?" procedure, the sexted number from the extent posts code for the attempts docked number addition.

[/]A copy of the Office Letter is enclosed.

#### IDENTIFICATION OF PERSON MAKING STATEMENT

2.	1,	Janet I. Cord
	(type or print name of person signing below)	
	state the following	

#### ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each stem as applicable)

- A. [/]"Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. 1 821(c) and 37 C.F.R. 1 822 and 1.823.
- B. [/]An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. 1.821(d).
- C. [] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. 1.821(e) and 1.824.
- D. [ ] Please transfer to this application, in accordance with 37 C.F.R. 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of: Group No.: Serial No.: Filed: Examiner: For.

The Computer readable form(s) of applicant's other application corresponds or compares to the "Sequence Identifier(s)" of this application as follows:

Computer Readable Form (other applications)

"Sequence Identifier" (this application)

- NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall he accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified. " 37 C.F.R. 1.821(e).
  - E. I.I. A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 C.F.R. 1.821(f).
    - [ ] Because the statement is not made by a person registered to practice before the Office, the Statement is verified as required in 37 C.F.R. 1 821(b)
  - F [/] Because this submission is made in fulfilling the requirement under 37 C.F.R. 1.821(g), a statement that the submission includes no new matter
    - 1 Because the statement is not made by a person registered to practice before the Office, the statement is verified, as required in 37 C.F.R. 1.821(g).

#### STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [] Each computer readable form submitted nthis application, including those forms requested to be transferred from applicant's other application, is the sameas the "Sequence Listing" to which it is indicated to relate.
- B. I/IAII papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

#### STATES

5. Applicant is

| | a small entity:

#### EXTENSION OF TERM

6.

NOTE 3.7 C.F.R. § 1.70445)\*... an applicant shall be deemed to have failed to engage in reasonable glores to conclude processing or examination of an application for the camulative total of any periods of time in exects aftern mentals that are taken to reply to any redice are actively the Office notating any rejection, objection, argument, or alther request, measuring such three-month period fromthe date the notice or action was malied or given to the applicant, in this case the period of adjustments of both in 1.728 shall be reduced by the number of thest, if any, beginning on the day of the the date that is three months after the shand multing or transmission of the Office communication notifying the applicant of the rejection, projection, argument, or other requestion density and that the reply was effect. The period, or shortened stampary period, for regly that is set in the Office action or notice has no affect on the three-month period set faith in this programment.

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Fund Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the Surveneed studiory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and for entry of an udditional amendment offer expiration of the shortened statutory period intest the timely if hel treppose placed the upplication in condition for allowance of Cooners, (in Notice of Appeal has been filed within the shortened statutory period, the period has coased to run." Notice of Dec. 10, 1985 (1061 O.C. 34-35)

- NATE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.
- 7 The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable)

(a) [ ] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below.

Extension (months)	Fee for other than small entity	Fee for small entity
one month	\$ 130.00	\$ 65.00
two months	\$ 490.00	\$ 245.00
three months	\$ 1,110.00	\$ 555.00
four months	\$ 1,730 00	\$ 865.00
five months	\$ 2,350.00	\$ 1,175.00
	Fre S	

If an additional extension of time is required, please consider this a petition therefor

	(check and complete the next item, if applicable)
	[ ] An extension for months has already been secured, and the fee paid therefor of \$ is deducted from the total feedure for the total months of extension now requested.
	Extension fee due with this request \$
	OR
	(b) [/]Applicant believes that no extension of term is required. However, this conditional pctition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a pctition and fee for extension of time.
	FEE PAYMENT
8.	[ ] Attached is a check in the sum of \$
	[ ] Charge Account No. 12-0425 the sum of \$
	[✓] Please charge Account No <u>12-0425</u> for any fees which may be due by this paper.

#### FEE DEFICIENCY

0

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional feesure necessary to cover the additional time consumed in multiple up original deficiency. If the neuromen, is e-month period has expired before the deficiency is noted and convocted, the application is held abundaned. In those miscures where authorization of charge is included, processing delays are encountered in returning the papers to the PTO finance Branch order to apply these charges prior to action on the cases, Josinovization to charge the depast account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1085 (O. 3) 1-33.

16. [/]If any additional extension and/or fee is required, charge Account No.12-0425.

### SIGNATURE(s)

	(type or print name of person signing statement)
	Signature
Date	
P.O. Address of Signatory	
(Wapplicable)  Tel. No. ( )  Rog. No.	Inventor     Assignee of complete interest     Person authorized to sign on behalf of assignee     Practitioner of record     Field under Rule 3-4(a)     Registration No.     Other     Opecify identity of person signing)
(complete the follo	wing, if applicable)
PROGENIKA BIOPHARMA, S.A. (type name of assignee)	
PARQUE TECNOLOGICO DE BIZKAIA EDIFICIO 801B 48150 DERIO, VIZCAYA, SPAIN Address of assignee	-
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. 3.73(b)" is a	ttached.
Assignment recorded in PTO on JANUARY 16, 20 Red 020390 Frame 0770	98
Reg. No.: 33,778	SIGNATURE OF PRACTITIONER Janet 1. Cord
Tel. No.: (212)708-1935	(type or print name of practitioner)
Customer No.: 90140,	P.O. Addrees
00140 Patent thademark oppose	c/o Ladas & Parry LLP 26 West 61st Street New York, N.Y. 10023